290307-40-3

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-(1-hydroxy-1-methylethyl)pyridine is used as a building block in organic synthesis for the creation of various bioactive compounds. Its unique structure allows for the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 5-Bromo-2-(1-hydroxy-1-methylethyl)pyridine is utilized as a key intermediate in the synthesis of drugs with therapeutic potential. Its presence in the molecular structure can contribute to the desired pharmacological properties of the final product.
Used in Anti-inflammatory Applications:
5-Bromo-2-(1-hydroxy-1-methylethyl)pyridine has been studied for its anti-inflammatory properties, making it a potential candidate for the development of anti-inflammatory drugs. It may help in reducing inflammation and associated symptoms in various conditions.
Used in Antitumor Applications:
This chemical compound has also been investigated for its antitumor activity, indicating its potential use in the development of anticancer drugs. It may contribute to the inhibition of tumor growth and the prevention of cancer progression.
Used in Antimicrobial Applications:
5-Bromo-2-(1-hydroxy-1-methylethyl)pyridine has shown antimicrobial properties, suggesting its use in the development of antimicrobial agents. It may help in combating bacterial and fungal infections by inhibiting the growth of microorganisms.

InChI:InChI=1/C8H10BrNO/c1-8(2,11)7-4-3-6(9)5-10-7/h3-5,11H,1-2H3

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 67-64-1 acetone 
• 75-16-1 methylmagnesium bromide 
• 29682-15-3 methyl 5-bromopicolinate 

Downstream Products

• 1207877-91-5 2-(5-(5-amino-2-methylphenyl)pyridin-2-yl)propan-2-ol 
• 1207746-99-3 2-{5-[2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl}propan-2-ol 
• 1207745-58-1 2-(5-(5-((5-chloropyridin-2-yl)thio)-2-(4-fluorophenyl)oxazol-4-yl)pyridin-2-yl)propan-2-ol 
• 1207747-00-9 2-{5-[5-bromo-2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl}propan-2-ol 
• 1026683-01-1 3-(3-cyclopropoxy-4-difluoromethoxy-phenyl)-3-{6-[1-methyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-pyridin-3-yl}-2-(1-oxy-pyridin-3-yl)-propionic acid 
• 290307-35-6 (+/-)-4-{2-[(3-cyclopropyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy])ethyl)pyridyl]ethyl}pyridine 
• 290307-34-5 (+/-)-[(3-cyclopropyloxy-4-difluoromethoxy)phenyl]{2-[1-methyl-1-(2-trimethylsilylethoxy)methoxy]ethyl-pyridin-5-yl}methanol 
• 290307-36-7 (3-cyclopropyloxy-4-difluoromethoxyphenyl)-{2-[2-((2-trimethylsilylethoxy) methoxy)propane-2-yl]5-pyridyl}chloromethane 
• 552287-65-7 (+/-) 3-{2-(3-cyclopropyloxy-4-difluoromethoxyphenyl)-2-[2-(2-hydroxypropan-2-yl)5-pyridyl]ethyl}pyridine-N-oxide 
• 2070867-74-0 5-bromo-2-(2-fluoropropan-2-yl)pyridine 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

PYRIMIDINE PDE10 INHIBITORS

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS

Cycloalkylnitrile pyrazole carboxamides as JAK inhibitors useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer are provided.

Preparation of novel substituted haloarene compounds

This invention relates to a new process for the preparation of novel substituted haloarene compounds of the formula I or IV: respectively, wherein R1, R2, R3, R4, R5, X, and Y are as defined herein, that comprises a novel and efficient selective mono-lithiation of a dihaloarene of the formula II or V: respectively, by an organo-lithium compound in the presence of a carbonyl reactant of the formula III: wherein R1 and R2 are as defined herein. In the process of the instant invention, the newly formed lithiated haloarene is sequentially quenched in situ by the carbonyl reactant to form said substituted haloarene. The process is suitable for batch or continuous flow systems. The substituted haloarenes produced by the process of the present invention are useful intermediates in the preparation of N-aryl or N-heteroaryl substituted pharmaceutically active compounds that include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated.